Thermo Fisher Scientific Inc (TMO)
SobrevaloradaFundamental
61
Precio
$675.05
Capitalización Bursátil
$250.91B
Parte 1 · Cuánto vale la empresa
Resumen
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$46.34B
Últimos 12 meses (hasta 27/6/2026)
Beneficio Neto
$6.97B
Últimos 12 meses (hasta 27/6/2026)
Flujo de Caja Libre
$6.29B
Patrimonio Neto Total
$53.41B
Pasivo Total
$56.93B
Ratio de Liquidez
1.55
Cobertura de Intereses
5.46
Deuda/EBITDA
3.62
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$437.42
Precio Actual
$675.05
Margen de Seguridad
-54.3%
Rango de Valor Justo
$284.32 - $590.52
Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.
Métodos de Estimación
Métricas de Valoración
Ratio P/E
36.31
ROE
12.6%
Ratio P/B
4.74
P/FCF
34.11
Margen Bruto
-
ROIC
6.6%
Radar de Rentabilidad
Creación de Valor (Ventaja Competitiva)
ROIC
6.6%
WACC
8.3%
ROIC − WACC
-1.7 pp
El ROIC está por debajo del coste del capital: la empresa destruye valor por cada dólar invertido.
Criterios de Análisis Fundamental
Superado (19)
- EPS shows upward trend
- EPS CAGR 13.95%
- Price CAGR 15.76%
- ROIC 6.6%
- Debt/Equity ratio
- Operating Margin 17.6%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 13.3%
- Revenue Growth 5Y 6.7%
- Analyst Consensus 81% Buy
- Earnings Surprise avg 3.2%
- Earnings Quality (OCF/NI) 1.29
- Share Dilution -1.4%
- Piotroski F-Score 5/9
Fallido (7)
- P/FCF 34.11
- P/B Ratio 4.74
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG Ratio 16.99
- Net Margin Trend 15.0% vs 15.2%
No disponible (2)
- Gross Margin NaN%
- Dividend Payout NaN%
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Participaciones institucionales
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Marc N. Casper | Chairman & CEO | 57 |
| Mr. Gianluca Pettiti | President, COO & President of Products and Technologies | 46 |
| Mr. James R. Meyer | Senior VP & CFO | 45 |
| Mr. Joseph R. Holmes | VP & Chief Accounting Officer | 45 |
| Mr. Ryan J. Snyder | Senior VP & Chief Information Officer | - |
| Dr. Karen E. Nelson Ph.D. | Chief Scientific Officer | - |
| Mr. Rafael Tejada | Vice President of Investor Relations | - |
| Mr. Thomas Bailey Shropshire Jr. | Senior VP and General Counsel | - |
| Ms. Sandy B. Pound | VP & Chief Communications Officer | - |
| Mr. Alan J. Malus | Senior Vice President of Strategy & Corporate Development | 65 |
Riesgo de Auditoría
2
Riesgo del Consejo
7
Riesgo de Compensación
10
Riesgo de Derechos del Accionista
1
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Documentos
- Ver documento
Informe anual (10-K)
Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.
Presentado el 2026-02-26
- Ver documento
Informe trimestral (10-Q)
Una actualización del desempeño financiero de los últimos tres meses.
Presentado el 2026-07-31
- Ver documento
Informe de hecho relevante (8-K)
Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.
Presentado el 2026-07-23
via SEC EDGAR
Historial de Resultados
via SEC EDGAR
Latest News
Recent headlines for TMO, sourced from Markets Gazette.
- 5/25/2026POSITIVEIf You Invested $1000 In Thermo Fisher Scientific Stock 20 Years Ago, You Would Have This Much Today
An investment of $1000 in Thermo Fisher Scientific (TMO) stock 20 years ago would have yielded a substantial return, illustrating the company's long-term growth trajectory. While the exact final value is not provided in this snippet, historical performance data suggests significant capital appreciation. This underscores Thermo Fisher's consistent operational success and market leadership in the life sciences and diagnostics sectors. Investors considering TMO should note its history of innovation and strategic acquisitions, which have contributed to its robust financial performance and shareholder value creation over the past two decades.
- 3/12/2026POSITIVEHere's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today
An investment of $100 in Thermo Fisher Scientific (TMO) 15 years ago would have grown to approximately $1,040 today, representing a substantial 940% return. This performance significantly outpaced the broader market during the same period. The company's consistent growth trajectory, driven by its diversified portfolio in life sciences, diagnostics, and laboratory products, has been a key factor in its stock's appreciation. Investors who held TMO stock have benefited from its strong operational execution and strategic acquisitions, underscoring its resilience and long-term value creation potential.
- 3/2/2026NEUTRALHere's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today
A retrospective analysis highlights the remarkable performance of Thermo Fisher Scientific, revealing how a $100 investment made two decades ago would have generated substantial returns for today's investors. While this study doesn't provide direct future guidance, it underscores the company's ability to create long-term value, driven by its leadership in life sciences, diagnostics, and research. Consistent growth and innovation have allowed Thermo Fisher to solidify its market position, transforming a modest initial capital into a significantly larger sum. For investors, this serves as a reminder of the importance of patience and selecting companies with strong fundamentals and a lasting competitive advantage.
via Markets Gazette